The type of Aβ-related neuronal degeneration differs between amyloid precursor protein (APP23) and amyloid β-peptide (APP48) transgenic mice
- Ajeet Rijal Upadhaya†1,
- Frederik Scheibe†1,
- Irina Kosterin1,
- Dorothee Abramowski2,
- Janina Gerth3,
- Sathish Kumar3,
- Stefan Liebau4,
- Haruyasu Yamaguchi5,
- Jochen Walter3,
- Matthias Staufenbiel2 and
- Dietmar Rudolf Thal1Email author
© Rijal Upadhaya et al.; licensee BioMed Central Ltd. 2013
Received: 2 November 2013
Accepted: 6 November 2013
Published: 18 November 2013
The deposition of the amyloid β-peptide (Aβ) in the brain is one of the hallmarks of Alzheimer’s disease (AD). It is not yet clear whether Aβ always leads to similar changes or whether it induces different features of neurodegeneration in relation to its intra- and/or extracellular localization or to its intracellular trafficking routes. To address this question, we have analyzed two transgenic mouse models: APP48 and APP23 mice. The APP48 mouse expresses Aβ1-42 with a signal sequence in neurons. These animals produce intracellular Aβ independent of amyloid precursor protein (APP) but do not develop extracellular Aβ plaques. The APP23 mouse overexpresses human APP with the Swedish mutation (KM670/671NL) in neurons and produces APP-derived extracellular Aβ plaques and intracellular Aβ aggregates.
Tracing of commissural neurons in layer III of the frontocentral cortex with the DiI tracer revealed no morphological signs of dendritic degeneration in APP48 mice compared to littermate controls. In contrast, the dendritic tree of highly ramified commissural frontocentral neurons was altered in 15-month-old APP23 mice. The density of asymmetric synapses in the frontocentral cortex was reduced in 3- and 15-month-old APP23 but not in 3- and 18-month-old APP48 mice. Frontocentral neurons of 18-month-old APP48 mice showed an increased proportion of altered mitochondria in the soma compared to wild type and APP23 mice. Aβ was often seen in the membrane of neuronal mitochondria in APP48 mice at the ultrastructural level.
These results indicate that APP-independent intracellular Aβ accumulation in APP48 mice is not associated with dendritic and neuritic degeneration but with mitochondrial alterations whereas APP-derived extra- and intracellular Aβ pathology in APP23 mice is linked to dendrite degeneration and synapse loss independent of obvious mitochondrial alterations. Thus, Aβ aggregates in APP23 and APP48 mice induce neurodegeneration presumably by different mechanisms and APP-related production of Aβ may, thereby, play a role for the degeneration of neurites and synapses.
KeywordsIntracellular amyloid β-protein Extracellular amyloid β-protein Mitochondria Dendrites Toxicity Degeneration
The deposition of amyloid Aβ-peptide (Aβ) in the human brain and the formation of neurofibrillary tangles (NFTs) are histopathological hallmarks of Alzheimer’s disease (AD) [1, 2]. Neuron loss, neuritic and synaptic degeneration are seen in addition to Aβ-plaque deposition and NFT formation and are assumed to represent the morphological correlative of cognitive decline [3–5].
Aβ is a proteolytic fragment derived from the amyloid precursor protein (APP) by β- and γ-secretase cleavage [6, 7]. Aβ is the major component of extracellular senile plaques in the AD brain  and it has been considered to play a central role in AD pathogenesis . In addition to extracellular Aβ-deposition, intracellular Aβ occurs in nerve cells in the AD brain [9, 10] and in mouse models for AD [11–13]. The role of intracellular Aβ in neurodegeneration and the development of AD is discussed controversially. Mutant intracellular Aβ has been shown to induce hippocampal cell loss associated with endoplasmic reticulum stress and mitochondrial alterations in cell culture . Memory impairment in APP-transgenic mice has been observed even after reduction of plaques. In these animals increased levels of intraneuronal Aβ were reported . The new APP48 mouse model expresses a proenkephalin signal peptide (SPENK)-human wild type Aβ42 construct in neurons of the central nervous system (CNS), exhibits intracellular Aβ-aggregates in neurons in the absence of Aβ-plaques, and develops CA1 neuron loss and motor deficits . The name APP48 mouse is misleading because Aβ is produced independent from APP in these mice but we used the name APP48 mouse here because this mouse model was already introduced to the scientific community with this name . Although Aβ production in APP48 mice differs from APP-derived Aβ production and does not model AD, APP48 mice allow the analysis of intracellular Aβ toxicity independent of APP under artificial conditions. The APP23 mouse is an Aβ-plaque producing mouse model, which overexpresses human APP with the Swedish mutation (KM670/671NL) in CNS neurons. It exhibits dendrite degeneration, loss of CA1 neurons and of asymmetric synapses in the frontocentral cortex [17–19]. In this mouse model Aβ is generated by proteolytic processing of APP by β- and γ-secretases. It accumulates extracellularly in Aβ plaques and in intracellular aggregates [13, 20]. Together, these mouse models offer the possibility to compare the effect of Aβ placed into the endoplasmic reticulum and the Golgi apparatus in APP48 mice with Aβ cleaved from APP in a post-Golgi compartment [21, 22] in APP23 mice. Both mice have been demonstrated to express high amounts of the transgene mRNA in neurons of the neocortex and hippocampus in a similar distribution pattern [16, 20] providing comparable transgene expression levels in the respective neurons of these mouse models. Here, we investigated 1) any pathological abnormalities associated with APP-independent intracellular Aβ accumulation in APP48 mice and 2) whether APP and Aβ production by β- and γ-secretase is critical for neurodegeneration in APP23 mice rather than the mere presence of the Aβ peptide as in APP48 mice.
To address these objectives we studied dendritic morphology of frontocentral layer III pyramidal cells and synapse densities in the frontocentral cortex and the hippocampal sector CA1 of APP48 mice in comparison with APP23 and wild type mice. We determined the numbers of neurons in the frontocentral cortex as well as in the hippocampal sector CA1, and compared ultrastructural changes in neurons of APP23, APP48, and wild type mice.
APP48 mice were generated as described previously  and continuously back-crossed to C57BL/6. A murine Thy-1 expression cassette was used encoding the rat proenkephalin signal sequence followed by human wild type Aβ1-42 to drive neuron-specific expression of human wild type Aβ1-42. APP23 mice were generated as described previously  and continuously back-crossed to C57BL/6. The same murine Thy-1 cassette was used to drive neuron-specific expression of human APP751 with the Swedish double mutation 670/671 KM → NL. Heterozygous female APP23 mice (3 months, n = 12; 15 months, n = 17) and female and male APP48 mice (3 months, n = 12; 18 months, n = 17) were analyzed. As control, respective female and male wild type littermates of 3 (n = 14), 15 (n = 10), and 18 months (n = 10) were used.
Animals were treated in agreement with the German and Swiss laws for the use of laboratory animals.
Tissue preparation and DiI tracing
For DiI tracing the brains of 3 and 18-months-old APP48, 3 and 15-month-old APP23, and of 3 and 15-18-month-old wild type mice were studied. Mice were anesthetized. Perfusion was performed transcardially with Tris-buffered saline (TBS) with heparin (pH 7.4) followed by the injection of 0.1 M PBS (pH 7.4) containing 2.6% paraformaldehyde (PFA), 0.8% iodoacetic acid, 0.8% sodium periodate and 0.1 M D-L lysine. The brains were removed in total and post-fixed in 2.6% phosphate-buffered PFA (pH 7.4) containing 0.8% iodoacetic acid, 0.8% sodium periodate and 0.1 M D-L lysine . Three days later a single crystal (0.3 mm3) of the carbocyanine dye DiI (Molecular Probes, Eugene, OR, USA) was implanted into the left frontocentral cortex, 1 mm rostrally from the central sulcus, 2 mm laterally from the middle line and 1 mm deep in the cortex as reported earlier . This dye allows precise Golgi-like tracing of neurons in post-mortem fixed tissue in a quality similar to in vivo tracing methods . After incubation in 2.6% phosphate-buffered PFA for at least 3 months at 37°C, 100 μm thick coronal vibratome sections were cut. All sections of a given mouse brain were separately stored and continuously numbered. Sections were temporarily mounted in TBS for microscopic analysis.
Microscopic and quantitative analysis
In layer III of the frontocentral cortex of the right hemisphere, contralateral to the implantation site of the tracer, the morphology of traced commissural neurons was examined. The traced neurons were assigned to different types according to their morphology  (Additional file 1). Then the number of traced commissural neurons of each type in wild type mice was counted and compared with that in APP23 and APP48 mice. For qualitative and quantitative analysis 10 consecutive sections (100-μm thickness each) representing a tissue block of 1 mm thickness were studied for each mouse. Analysis started at the anterior commissure setting the caudal limit of the investigated tissue block. For each coronal section, the medial boundary of the region investigated was set as the vertical line at the cingulum that separated the cingulate cortex from secondary motor cortex (M2). The horizontal boundary was set as the horizontal line separating the primary somatosensory cortex (S1) from the insular cortex.
For the qualitative analysis a laser scanning confocal microscope (Leica TCS NT, Leica, Bensheim, Germany) was used. Stacks of 2D images were superimposed digitally using the Image J Image Processing and Analysis software (NIH, Bethesda, MD, USA), and 3D data sets were generated for the visualization of neurons with their entire dendritic tree. For quantification, traced neurons in layer III were counted in the region of interest in 10 consecutive sections of the tissue block taken for qualitative and quantitative analysis using a fluorescence microscope (Leica DMLB, Leica). In so doing, we analyzed a cortex volume of 5–6 mm3 in each mouse. Mean and median values of the number of traced neurons were calculated and compared between wild type, APP23, and APP48 mice.
Immunohistochemistry was performed for the visualization of Aβ pathology as well as dendritic morphology in APP48 and APP23 mice. After formic acid pretreatment free-floating sections were incubated in goat anti-mouse immunoglobulin (IgG) to block cross-reactions with intrinsic mouse IgG as previously described . To detect Aβ-positive material the sections were stained with monoclonal antibodies specifically detecting the C-terminus of Aβ42 (MBC42 , 1/200). In APP23 mice anti-Aβ17-24 (4G8; 1/5000, Sigma-Aldrich, St. Louis, USA) was used to stain Aβ-deposits regardless of the Aβ40 or Aβ42 C-terminus. MBC40 ( , 1/20) antibodies detecting exclusively the C-terminus of Aβ40 were used in APP23 mice as well. N-terminal-truncated and pyroglutamate modified AβN3pE was detected with anti-AβN3pE (polyclonal rabbit, 1/100, additional microwave pretreatment, IBL International GmbH, Hamburg, Germany ). Phosphorylation of serine 8 of Aβ was detected with antibodies against phosphorylated Aβ (pAβ; SA5434, 1/5; 1E4E11, 1/50, additional microwave pretreatment [27, 28]). The primary antibodies were detected with a biotinylated secondary antibody and the ABC complex (Vectastain, Vector laboratories (Burlingame, CA. USA)), and visualized with DAB . Sections were mounted in Eukitt© (Kindler, Freiburg, Germany). The immunostained sections were analyzed with a Leica DMLB fluorescence microscope (Leica, Bensheim, Germany). Positive and negative controls were performed.
Protein extraction from brain tissue
Protein extraction was carried out from female APP23 (n = 4), APP48 (n = 4), and wild type littermates (n = 4) mouse brains, aged 9–11 months. Mice of this age were taken to demonstrate the differences in the biochemical distribution of Aβ in APP23 and APP48 mice.
Fresh frozen forebrain (0.4 g) was homogenized in 2 ml of 0.32 M sucrose dissolved in Tris-buffered saline (TBS) containing a protease and phosphatase inhibitor-cocktail (Complete and PhosphoSTOP, Roche, Mannheim, Germany) with Micropestle (Eppendorf, Hamburg, Germany) followed by sonication. The homogenate was centrifuged for 30 min at 14.000 × g at 4°C. The supernatant (S1) with the soluble and dispersible fraction not separated from one another was kept. The pellet (P1) containing the membrane-associated and the insoluble, plaque-associated fraction was resuspended in 2% SDS.
Ultracentrifugation of the supernatant S1 at 175.000 × g was used to separate the soluble, i.e. the supernatant after ultracentrifugation (S2), from the dispersible fraction, i.e. the resulting pellet (P2). The pellet P2 with the dispersible fraction was resuspended in TBS.
The SDS-resuspended pellet P1 was centrifuged at 14.000 × g. The supernatant (S3) was kept as membrane-associated SDS-soluble fraction. The pellet (P3) that remained was dissolved in 70% formic acid and dried in a vacuum centrifuge (Vacufuge, Eppendorf, Hamburg, Germany) and reconstituted in 100 μl of 2X LDS (lithium dodecyl sulfate) sample buffer (Invitrogen, Carlsbad, CA, USA) followed by heating at 70°C for 5 min. The resultant sample was considered as insoluble, plaque-associated fraction . The total protein amounts of soluble, dispersible, and membrane-associated fractions were determined using BCA Protein Assay (Bio-Rad, Hercules, CA, USA).
SDS-PAGE and western blot analysis
For SDS-PAGE, soluble (S2), dispersible (P2), membrane-associated (SDS-soluble; S3), and insoluble, plaque-associated (formic acid soluble; P3) fractions (50 μg total protein) were electrophoretically resolved in a precast NuPAGE 4-12% Bis-Tris gel system (Invitrogen). The protein load was controlled either by Ponceau S staining or β-actin (C4, 1/1000, Santa Cruz Biotechnology, Santa Cruz, CA, USA) immunoblotting.
Aβ was detected by western blotting with anti-Aβ1-17 (6E10, Covance, Dedham, USA, 1/1000). Blots were developed with an ECL detection system (Supersignal Pico Western system, ThermoScientific-Pierce, Waltham, MA, USA) and illuminated in ECL Hyperfilm (GE Healthcare, Buckinghamshire, UK).
For analysis of Aβ by ELISA, forebrain homogenates from APP23 and APP48 mice of each age group (2–3 months: n = 6 (APP23), 6 (APP48); 15–18 months: n = 7 (APP23), 8 (APP48)) were homogenized, centrifuged and loaded on sandwich ELISA plates for quantification of Aβ peptides (Aβ42: ELISA from Innogenetics, Ghent, Belgium) as previously described . Standard curves were prepared with synthetic Aβ1-42 purchased from Bachem and diluted in extracts of non-transgenic mouse forebrain prepared in parallel as described above. Each sample was analyzed in duplicate.
Six APP23, six APP48, and six wild type mice at the ages of 3 and 15-18-months, respectively, were chosen randomly for stereology. One brain section of the frontocentral cortex already quantified for the number of DiI-traced neurons was selected by chance and stained with aldehyde fuchsin-Darrow red. Quantification of neurons was performed according to the principles of unbiased stereology . The frontocentral cortex volume was defined as the volume of the subfields M2, M1, S1 starting at the level of the anterior commissure as described previously . The CA1 volume was measured in serial 100 μm thick sections of the entire mouse brain at 5x magnification. Neurons were counted in three different, randomly chosen microscopic fields (40x objective magnification) of an aldehyde fuchsin - Darrow red stained section of the frontocentral cortex and CA1, respectively. For optical dissection, stacks of 10 images in 2 μm focus distance were generated for each microscopic field. Only those neurons having nuclei with dark and round nucleoli visible in the center of soma in one of the stack-images were considered for quantification using the ImageJ software (NIH, Bethesda, USA). The number of neurons in the frontocentral cortex and CA1 was calculated on the basis of the respective reference volumes and neuron densities.
Electron microscopy, immunoelectron microscopy and semiquantitative assessment of synapse densities and mitochondrial alterations
100 μm thick vibratome sections of the frontocentral cortex and of the hippocampus from six wild type, six APP23, and six APP48 mice, aged 3 and 15–18 months respectively, were flat-embedded in Epon (Fluka, Germany). A second vibratome section from each animal and region was flat embedded in LR-White-Resin (Hard-grade Acrylic Resin; London Resin Company, Berkshire, UK). A part of the frontocentral cortex covering all six cortical layers was dissected under microscopic control and pasted on Epon blocks with a drop of Epon. Likewise, a part of the CA1 subfield of the hippocampus with adjacent stratum oriens and radiatum was cut and pasted on a second Epon block ultrathin sections were cut at 70 nm. Epon sections were block stained with uranyl acetate and lead citrate, and viewed with a Philips EM400T 120KV (Philips, Eindhoven, The Netherlands), a Zeiss EM10 (Zeiss, Oberkochen, Germany), or a JEM-1400 (JEOL, Tokyo, JP) electron microscope. LR-White sections were immunostained with anti-Aβ42 (MBC42) and anti-Aβ1-17 (6E10, Covance, Dedham, USA, 1 mg/ml) antibodies and visualized with anti-mouse secondary antibodies (Aurion Immuno Gold Reagents & Accessories, Wageningen, The Netherlands) labeled with 10 nm nanogold particles. Digital pictures were taken.
Digital pictures from Epon embedded sections were taken from 20 soma- and plaque-free neuropil areas located in layers II-VI at 4600-times magnification. The numbers of the symmetric and asymmetric synapses were counted and the length of the synapses was determined with the ImageJ software (NIH, Bethesda, USA). The synaptic density was determined separately for symmetric and asymmetric synapses according to DeFelipe et al.  (synaptic density = number of synapse-profiles in a given area / length of synaptic profiles). These semiquantitative data were used to compare the synaptic densities between the different mouse lines. Asymmetric and symmetric synapses were distinguished according to published criteria [33, 34].
Synaptic densities in the CA1 regions were measured in 10 randomly taken pictures of the stratum oriens and in 10 randomly taken pictures of the stratum radiatum at 4600-times magnification.
Determinations of the parameters employed for quantification of mitochondrial alterations in neurites and nerve cell somata
Percentage of altered mitochondria in nerve cell somata =
Percentage of altered mitochondria in neurites (axons and dendrites) =
Mitochondrial volume density in the nerve cell somata =
Mitochondrial volume density in neurites =
Volume density of altered mitochondria in the nerve cell somata =
Volume density of altered mitochondria in neurites =
SPSS 19.0 (SPSS, Chicago, IL, USA) software was used to calculate statistical tests. Non-parametric tests were used to compare wild type, APP23, and APP48 mice. p-values were corrected for multiple testing using the Bonferroni method. Parametric data were analyzed by ANOVA with subsequent Games-Howell post-hoc test to correct for multiple testing or using the Welch test. The results of the statistical analysis are summarized in Additional file 2.
Different patterns of Aβ-pathology in APP23 and APP48 mice
Modified Aβ such as AβN3pE was detected in a large number of plaques in 15-month-old APP23 mice (Figure 2c). In APP48 mice only few dendritic threads exhibited AβN3pE at 3 months of age (Figure 2d) whereas at 18 months of age a significant number of AβN3pE-positive inclusions was observed as shown previously . Phosphorylated Aβ (pAβ) in APP23 mice was detected in plaques of 15 months old APP23 mice (Figure 2e). Intraneuronal pAβ in APP23 mice was apparent as previously reported in APP-PS1 transgenic animals . Only single pAβ-positive threads were stained in 3-month-old APP48 mice (Figure 2f) whereas a few more pAβ-positive threads, grains and somatic granules were observed at 18 months of age.
To document the distribution of Aβ aggregates we analyzed brain homogenates of 9-11-month-old APP23 and APP48 mice for Aβ in the soluble (S2), dispersible (P2), membrane-associated (S3) and insoluble fraction (P3). APP23 mice exhibited soluble, dispersible, membrane-associated and insoluble, plaque-associated Aβ (Figure 3b) as reported previously in detail . In contrast, APP48 mice only exhibited dispersible, membrane-associated and insoluble, aggregated Aβ whereas soluble Aβ was not detectable (Figure 3b).
Degeneration of neurites and asymmetric synapses in APP23 but not in APP48 mice
The number of asymmetric synapses increased with age in the frontocentral neocortex of wild type, APP23, and APP48 mice (Figure 6a, Additional file 2d). Such an increase in the number of asymmetric synapses with age was not seen in the stratum radiatum and oriens of CA1 (Figure 6a, Additional file 2d). The number of symmetric synapses did not differ between 3 and 15-18-month-old mice of each genotype (Figure 6b, Additional file 2d).
Neuron loss in the CA1 subfield but not in the frontocentral cortex of APP48 and APP23 mice
The number of CA1 neurons was lower in 3- and 18-month-old APP48 mice compared to wild type animals indicating CA1 neuron loss in APP48 mice . A decrease in the number of CA1 neurons was also observed in 3- and 15-month-old APP23 mice in comparison to wild type animals (Figure 6c, Additional file 2e) .
In contrast, the number of neurons in the frontocentral cortex of 15-18-month-old APP23 and APP48 mice was not significantly different from that in wild type mice (Figure 6d, Additional file 2e) . Therefore, we did not analyze 3-month-old animals for the numbers of frontocentral neurons.
Increased mitochondrial alterations in neuronal somata of APP48 but not of APP23 mice
In the neuronal somata, the percentages and volume densities of altered mitochondria in frontocentral and CA1 neurons increased with age (Figure 8d, e, g, h, Additional file 2f, g). The volume densities of all, altered and healthy-looking mitochondria increased in APP23 and APP48 mice with age whereas in wild type animals such an increase was not observed (Figure 8f, i, Additional file 2h).
In neuritic processes, an increase or at least an increasing trend with age in the percentages and volume densities of altered mitochondria was observed in the frontocentral cortex of APP23, APP48 and wild type mice (Additional file 2k, Additional file 4a, b). In the stratum radiatum and oriens neurites of CA1, the percentages and volume densities of altered mitochondria in 15-month-old APP23 mice were lower than in wild type mice whereas no differences were observed between 3-month-old APP23 and wild type mice as well as between APP48 mice of any age and wild type mice (Additional file 2k, Additional file 4d, e). In neurites, the volume densities of all, healthy-looking and altered mitochondria did not increase with age (Additional file 2k, Additional file 4c, f).
This study shows that APP-derived extra-and intracellular Aβ pathology in 15-month-old APP23 mice was associated with neuron loss, synapse loss and with neuritic alterations in non-apoptotic and non-necrotic neurons. On the other hand, APP-independent intraneuronal accumulation of Aβ in the absence of Aβ plaques in APP48 mice lead to a loss of neurons in the CA1 region  and to mitochondrial alterations but not to neuritic and synaptic degeneration in non-apoptotic and non-necrotic neurons. Both, extracellular plaques in APP23 mice and intraneuronal Aβ in APP48 mice also contained AβN3pE and pAβ.
APP23 and APP48 mice differ considerably with respect to the mechanism of transgenic, human Aβ generation. Cleavage of Aβ from APP with the Swedish mutation as in APP23 mice occurs after APP internalization from the membrane in the early endosomal compartment [22, 39]. Once generated, Aβ is rapidly secreted into the extracellular space to a large extent. In APP48 mice, on the other hand, expression of Aβ42 with a cleaved signal sequence targets the released Aβ to the endoplasmic reticulum. Intracellular accumulation occurs in neurites and lysosomes whereas only very little Aβ42 is secreted into the extracellular space . APP48 mice lack human APP and its metabolites except for Aβ42 whereas APP23 mice produce more Aβ40 than Aβ42 and, in addition to Aβ, N- and C-terminal fragments of APP. A transgenic mouse expressing only Aβ40 with a similar construct as used in APP48 mice for Aβ42 did not show Aβ aggregation and neuronal degeneration . In double transgenic animals, expressing both Aβ42 and Aβ40 constructs, a similar pattern of pathological lesions was observed as in APP48 mice  indicating that Aβ40 has only a marginal effect in these animals.
Both, APP23 and APP48 mice exhibited intracellular Aβ in the lysosomal compartment and in mitochondria whereas early endosomal Aβ was not seen in APP48 mice. The distribution of the transgene mRNA in the neocortex and the hippocampus as well as the expression levels were quite similar in APP23 and APP48 mice [16, 20]. Accordingly, neocortical and hippocampal neurons did not vary much in the transgene expression levels in APP23 and APP48 mice. Both mouse models were used to determine the effects of Aβ under given artificial conditions. None of these two mouse models reflects human AD pathology because none showed significant neurofibrillary tangle pathology and both overexpressed a transgenic construct made to produce large amounts of Aβ [16, 20].
Neurite and synapse degeneration in APP23 and APP48 mice
APP23 mice showed dendritic degeneration in DiI-traced commissural neurons, loss of asymmetric synapses and dystrophic neurites whereas none of these pathologies was observed in APP48 mice. In this context, it is important to note that fibrillar Aβ was present in dendrites of APP48 mice indicating that the mere presence of intracellular Aβ was not sufficient to induce this pathology. Accordingly, neuritic degeneration and loss of asymmetric synapses may either require high concentrations of extracellular Aβ40/42 and/or the presence of APP and its metabolites including APP-derived Aβ as in APP23 mice. The amount of total Aβ42 determined by ELISA did not explain neuritic degeneration because APP48 mice contained more Aβ42 in the brain than 3–5 months old APP23 mice (see also ) although 5-month-old APP23 mice did already exhibit dendrite pathology as previously reported . Consistent with our observations, the prevalence of high levels of extracellular Aβ aggregates, e.g. soluble Aβ oligomers and protofibrils and Aβ plaques have been shown to be associated with altered synapse function [40–42]. Neuritic alterations were frequently seen near amyloid plaques [43, 44]. The electron microscopic detection of extracellular non-fibrillar and fibrillar Aβ-positive aggregates in association with dystrophic neurites in APP23 but not in APP48 mice further argues in favor of a critical role of extracellular Aβ in neuritic degeneration. Electrophysiological changes in response to extracellularly administered Aβ-aggregates were mainly reported for excitatory synapses [41, 42]. Since asymmetric synapses represent mainly excitatory (glutamatergic) synapses  the loss of these synapses likely represented the result of toxic interactions with Aβ aggregates. We have detected Aβ within few dystrophic neurites in APP23 mice indicating that we cannot exclude a contribution of intraneuronal Aβ to neuritic degeneration.
The Bri-Aβ42 mouse, that produces only extracellular Aβ42 derived from an ABri-Aβ42 construct did not show behavioral changes but Aβ plaques . Bri-Aβ40 mice expressing an ABri-Aβ40 construct did not even develop plaques. These findings may argue against a contribution of extracellular Aβ to Aβ toxicity. However, it is not yet clear whether the ABri-derived Aβ42 aggregates contain similar amounts of AβN3pE and pAβ as Aβ aggregates in APP23 or APP48 mice, whether APP expression or the presence of both, Aβ42 and Aβ40, is required for extracellular Aβ toxicity, or whether this mouse model did not produce enough Aβ42 to cause symptoms.
APPE693Δ transgenic mice produce Aβ lacking glutamate-22 (E22Δ). This mouse model does not develop amyloid plaques but APP-derived intracellular Aβ aggregates and synapse loss . Exogenous synthetic AβE22Δ also lead to synaptic alterations in hippocampal slice culture experiments or after intraventricular injection [46, 47]. As such, neuritic changes and/or synapse pathology can be explained by APP-derived Aβ production regardless of the presence of Aβ plaques whereas such changes were not reported in APP48, Bri-Aβ42 and Bri-Aβ40 mice, which produce non-APP derived Aβ. A further argument for a role of APP in Aβ toxicity in APP23 mice is our recent finding of a coaggregation of Aβ with C-terminal APP fragments in dispersible Aβ aggregates  supporting the hypothesis that APP is a molecular target of Aβ toxicity .
Mitochondrial alterations in APP23 and APP48 mice
APP-independent intraneuronal Aβ production and accumulation in 18-month-old APP48 mice was associated with more abundant structural mitochondrial alterations in somata of frontocentral nerve cells compared to APP23 and wild type mice. The increase of mitochondrial alterations in APP48 mice, however, was accompanied by the detection of Aβ in a moderate number of altered and non-altered neuronal somatic mitochondria whereas only few somatic mitochondria in APP23 mice exhibited Aβ and none in wild type animals. Several arguments suggest that the increase of mitochondrial alterations in APP48 mice was related to the presence of Aβ and may have functional consequences: 1) Aβ is capable of inducing apoptosis through the mitochondrial-caspase-3 pathway [49, 50], 2) mitochondrial Aβ levels are associated with the extent of mitochondrial dysfunction, oxidative stress and cognitive impairment in other AD mouse models and AD [51–55], and 3) histologically altered mitochondria showed a reduced number of christa membranes presumably providing a morphological correlate for an impairment of mitochondrial function; they were found most frequently in APP48 mice which also contained more mitochondrial Aβ than APP23 mice. For APP23 mice, however, we cannot rule out that trophic effects reported for APP expression  compensate Aβ toxicity to mitochondria.
It is noteworthy that only mitochondria in the nerve cell somata showed increased alterations in APP48 mice whereas mitochondria in distal dendrites and axons did not exhibit differences in volume density as well as in the percentage of alterations among APP23, APP48, and wild type mice. Thus, APP-independent, intraneuronal Aβ42 exhibited its major toxic effects on mitochondria close to its production site in APP48 mice, i.e. close to the endoplasmic reticulum. Biochemical assessment of respiratory chain complex I and complex IV, α-ketoglutarate dehydrogenase, and tricarboxylic acid cycle enzyme activity in APP48 and wild type mice did not show significant differences in forebrain homogenates (data not shown). However, the local effect in the soma is probably not sufficient to reduce the overall activities in a brain homogenate.
Two types of Aβ-induced neurodegeneration in the frontocentral cortex: somatic type and neuritic type
APP48 and APP23 mice both showed neuron loss in the CA1 region as previously described [16, 17, 19]. It was not accompanied by a reduction in synaptic density suggesting replacement of lost synapses by surviving neurons. Except for Aβ plaques in APP23 mice and intracellular Aβ in both transgenic animals, significant reduction of synapse densities and mitochondrial alterations could not be identified in this brain region possibly because the more vulnerable CA1 neurons die faster than altered neurons in the frontocentral cortex and do not accumulate at early stages of nerve cell degeneration. Since 3-month-old animals have more CA1 neurons than 15-18-month-old mice (Figure 6c) and the decrease in number was higher than the age-related loss of CA1 neurons in wild type mice it appears likely that the age-related loss of CA1 neurons is enhanced by Aβ toxicity in APP23 and APP48 mice.
Although both types of Aβ-related neurodegeneration were observed in artificial mouse models that were made to produce large amounts of Aβ there are arguments for the hypothesis that both mechanisms of Aβ-related neurodegeneration are relevant in AD: 1) synapse loss and dystrophic neurites especially around neuritic plaques are well known features of AD pathology [3, 60, 61] that might be explained in part by the neuritic type of Aβ-related neurodegeneration and 2) mitochondrial alterations are well known in AD cases as well  presumably indicative for somatic type neurodegeneration in the presence of intracellular Aβ .
Our data suggest two independent mechanisms by which Aβ causes neurodegeneration (Figure 10): a neuritic type and a somatic type. The neuritic type of neurodegeneration is characterized by a loss of asymmetric synapses, degeneration of dendrites, occurrence of dystrophic neurites and is associated with the occurrence of APP-derived extra- and intracellular Aβ aggregates in APP23 mice. The somatic type of neurodegeneration shows mitochondrial alterations in the neuronal soma but no changes in neurite morphology of non-necrotic and non-apoptotic cells. It is linked to intraneuronal accumulation of APP-independently produced Aβ and functional changes in APP48 mice . Both mechanisms may finally lead to a loss of neurons as observed in the hippocampal sector CA1 in APP23 and APP48 mice [16, 17]. Although these mechanisms for Aβ-related neurodegeneration have been found under artificial conditions in Aβ producing mouse models it is tempting to speculate that similar mechanisms occur in AD. APP-related production of extra- and/or intracellular Aβ, thereby, appears to be critical for neuritic and synaptic degeneration. As such, for the development of therapeutic strategies aimed at protecting neurons from AD-related degeneration it appears important to consider both types of Aβ-related neurodegeneration.
The authors thank Mr. E. Schmid (Department of Electron Microscopy, University of Ulm) for help with electron microscopy and Dr. E. Capetillo-Zarate (Weill Medical College of Cornell University, New York, USA) for technical help and for reading the manuscript.
- Alzheimer A: Über eine eigenartige Erkrankung der Hirnrinde. Allg Zschr Psych 1907, 64: 146–148.Google Scholar
- Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K: Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 1985, 82: 4245–4249. 10.1073/pnas.82.12.4245PubMed CentralView ArticlePubMedGoogle Scholar
- DeKosky ST, Scheff SW: Synapse loss in frontal cortex biopsies in Alzheimer’s disease: correlation with cognitive severity. Ann Neurol 1990, 27: 457–464. 10.1002/ana.410270502View ArticlePubMedGoogle Scholar
- Masliah E, Terry RD, DeTeresa RM, Hansen LA: Immunohistochemical quantification of the synapse-related protein synaptophysin in Alzheimer disease. Neurosci Lett 1989, 103: 234–239. 10.1016/0304-3940(89)90582-XView ArticlePubMedGoogle Scholar
- Terry RD, Peck A, DeTeresa R, Schechter R, Horoupian DS: Some morphometric aspects of the brain in senile dementia of the Alzheimer type. Ann Neurol 1981, 10: 184–192. 10.1002/ana.410100209View ArticlePubMedGoogle Scholar
- Haass C, Koo EH, Mellon A, Hung AY, Selkoe DJ: Targeting of cell-surface beta-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments. Nature 1992, 357: 500–503. 10.1038/357500a0View ArticlePubMedGoogle Scholar
- Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, Multhaup G, Beyreuther K, Muller-Hill B: The precursor of Alzheimer’s disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987, 325: 733–736. 10.1038/325733a0View ArticlePubMedGoogle Scholar
- Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 2002, 297: 353–356. 10.1126/science.1072994View ArticlePubMedGoogle Scholar
- D’Andrea MR, Nagele RG, Wang HY, Lee DH: Consistent immunohistochemical detection of intracellular beta-amyloid42 in pyramidal neurons of Alzheimer’s disease entorhinal cortex. Neurosci Lett 2002, 333: 163–166. 10.1016/S0304-3940(02)00875-3View ArticlePubMedGoogle Scholar
- Gouras GK, Tsai J, Naslund J, Vincent B, Edgar M, Checler F, Greenfield JP, Haroutunian V, Buxbaum JD, Xu H, Greengard P, Relkin NR: Intraneuronal Abeta42 accumulation in human brain. Am J Pathol 2000, 156: 15–20. 10.1016/S0002-9440(10)64700-1PubMed CentralView ArticlePubMedGoogle Scholar
- Takahashi RH, Milner TA, Li F, Nam EE, Edgar MA, Yamaguchi H, Beal MF, Xu H, Greengard P, Gouras GK: Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol 2002, 161: 1869–1879. 10.1016/S0002-9440(10)64463-XPubMed CentralView ArticlePubMedGoogle Scholar
- Tomiyama T, Matsuyama S, Iso H, Umeda T, Takuma H, Ohnishi K, Ishibashi K, Teraoka R, Sakama N, Yamashita T, Nishitsuji K, Ito K, Shimada H, Lambert MP, Klein WL, Mori H: A mouse model of amyloid beta oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. J Neurosci 2010, 30: 4845–4856. 10.1523/JNEUROSCI.5825-09.2010View ArticlePubMedGoogle Scholar
- Wirths O, Multhaup G, Czech C, Blanchard V, Moussaoui S, Tremp G, Pradier L, Beyreuther K, Bayer TA: Intraneuronal Abeta accumulation precedes plaque formation in beta-amyloid precursor protein and presenilin-1 double-transgenic mice. Neurosci Lett 2001, 306: 116–120. 10.1016/S0304-3940(01)01876-6View ArticlePubMedGoogle Scholar
- Umeda T, Tomiyama T, Sakama N, Tanaka S, Lambert MP, Klein WL, Mori H: Intraneuronal amyloid beta oligomers cause cell death via endoplasmic reticulum stress, endosomal/lysosomal leakage, and mitochondrial dysfunction in vivo. J Neurosci Res 2011, 89: 1031–1042. 10.1002/jnr.22640View ArticlePubMedGoogle Scholar
- Tampellini D, Capetillo-Zarate E, Dumont M, Huang Z, Yu F, Lin MT, Gouras GK: Effects of synaptic modulation on beta-amyloid, synaptophysin, and memory performance in Alzheimer’s disease transgenic mice. J Neurosci 2010, 30: 14299–14304. 10.1523/JNEUROSCI.3383-10.2010PubMed CentralView ArticlePubMedGoogle Scholar
- Abramowski D, Rabe S, Rijal Upadhaya A, Reichwald J, Danner S, Staab D, Capetillo-Zarate E, Yamaguchi H, Saido TC, Wiederhold KH, Thal DR, Staufenbiel M: Transgenic expression of intraneuronal Abeta42 but not Abeta40 leads to cellular Abeta lesions, degeneration and functional impairment without typical Alzheimer’s disease pathology. J Neurosci 2012, 32: 1273–1283. 10.1523/JNEUROSCI.4586-11.2012View ArticlePubMedGoogle Scholar
- Calhoun ME, Wiederhold KH, Abramowski D, Phinney AL, Probst A, Sturchler-Pierrat C, Staufenbiel M, Sommer B, Jucker M: Neuron loss in APP transgenic mice. Nature 1998, 395: 755–756. 10.1038/27351View ArticlePubMedGoogle Scholar
- Capetillo-Zarate E, Staufenbiel M, Abramowski D, Haass C, Escher A, Stadelmann C, Yamaguchi H, Wiestler OD, Thal DR: Selective vulnerability of different types of commissural neurons for amyloid beta-protein induced neurodegeneration in APP23 mice correlates with dendritic tree morphology. Brain 2006, 129: 2992–3005. 10.1093/brain/awl176View ArticlePubMedGoogle Scholar
- Rijal Upadhaya A, Capetillo-Zarate E, Kosterin I, Abramowski D, Kumar S, Yamaguchi H, Walter J, Fändrich M, Staufenbiel M, Thal DR: Dispersible amyloid β-protein oligomers, protofibrils, and fibrils represent diffusible but not soluble aggregates: Their role in neurodegeneration in amyloid precursor protein (APP) transgenic mice. Neurobiol Aging 2012, 33: 2641–2660. 10.1016/j.neurobiolaging.2011.12.032View ArticlePubMedGoogle Scholar
- Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, Ledermann B, Burki K, Frey P, Paganetti PA, Waridel C, Calhoun ME, Jucker M, Probst A, Staufenbiel M, Sommer B: Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA 1997, 94: 13287–13292. 10.1073/pnas.94.24.13287PubMed CentralView ArticlePubMedGoogle Scholar
- Haass C, Lemere CA, Capell A, Citron M, Seubert P, Schenk D, Lannfelt L, Selkoe DJ: The Swedish mutation causes early-onset Alzheimer’s disease by beta-secretase cleavage within the secretory pathway. Nat Med 1995, 1: 1291–1296. 10.1038/nm1295-1291View ArticlePubMedGoogle Scholar
- Rajendran L, Honsho M, Zahn TR, Keller P, Geiger KD, Verkade P, Simons K: Alzheimer’s disease beta-amyloid peptides are released in association with exosomes. Proc Natl Acad Sci USA 2006, 103: 11172–11177. 10.1073/pnas.0603838103PubMed CentralView ArticlePubMedGoogle Scholar
- Galuske RA, Schlote W, Bratzke H, Singer W: Interhemispheric asymmetries of the modular structure in human temporal cortex. Science 2000, 289: 1946–1949. 10.1126/science.289.5486.1946View ArticlePubMedGoogle Scholar
- Thal DR, Larionov S, Abramowski D, Wiederhold KH, van Dooren T, Yamaguchi H, Haass C, van Leuven F, Staufenbiel M, Capetillo-Zarate E: Occurrence and co-localization of amyloid beta-protein and apolipoprotein E in perivascular drainage channels of wild-type and APP-transgenic mice. Neurobiol Aging 2007, 28: 1221–1230. 10.1016/j.neurobiolaging.2006.05.029View ArticlePubMedGoogle Scholar
- Yamaguchi H, Sugihara S, Ogawa A, Saido TC, Ihara Y: Diffuse plaques associated with astroglial amyloid beta protein, possibly showing a disappearing stage of senile plaques. Acta Neuropathol 1998, 95: 217–222. 10.1007/s004010050790View ArticlePubMedGoogle Scholar
- Saido TC, Iwatsubo T, Mann DM, Shimada H, Ihara Y, Kawashima S: Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques. Neuron 1995, 14: 457–466. 10.1016/0896-6273(95)90301-1View ArticlePubMedGoogle Scholar
- Kumar S, Rezaei-Ghaleh N, Terwel D, Thal DR, Richard M, Hoch M, Mc Donald JM, Wullner U, Glebov K, Heneka MT, Walsh DM, Zweckstetter M, Walter J: Extracellular phosphorylation of the amyloid beta-peptide promotes formation of toxic aggregates during the pathogenesis of Alzheimer’s disease. EMBO J 2011, 30: 2255–2265. 10.1038/emboj.2011.138PubMed CentralView ArticlePubMedGoogle Scholar
- Kumar S, Wirths O, Theil S, Gerth J, Bayer TA, Walter J: Early intraneuronal accumulation and increased aggregation of phosphorylated Abeta in a mouse model of Alzheimer’s disease. Acta Neuropathol 2013, 125: 699–709. 10.1007/s00401-013-1107-8View ArticlePubMedGoogle Scholar
- Hsu SM, Raine L, Fanger H: Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981, 29: 577–580. 10.1177/29.4.6166661View ArticlePubMedGoogle Scholar
- Mc Donald JM, Savva GM, Brayne C, Welzel AT, Forster G, Shankar GM, Selkoe DJ, Ince PG, Walsh DM: The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. Brain 2010, 133: 1328–1341. 10.1093/brain/awq065PubMed CentralView ArticlePubMedGoogle Scholar
- Schmitz C, Hof PR: Recommendations for straightforward and rigorous methods of counting neurons based on a computer simulation approach. J Chem Neuroanat 2000, 20: 93–114. 10.1016/S0891-0618(00)00066-1View ArticlePubMedGoogle Scholar
- DeFelipe J, Marco P, Busturia I, Merchan-Perez A: Estimation of the number of synapses in the cerebral cortex: methodological considerations. Cereb Cortex 1999, 9: 722–732. 10.1093/cercor/9.7.722View ArticlePubMedGoogle Scholar
- Colonnier M: Synaptic patterns on different cell types in the different laminae of the cat visual cortex. An electron microscope study. Brain Res 1968, 9: 268–287. 10.1016/0006-8993(68)90234-5View ArticlePubMedGoogle Scholar
- Miranda R, Sebrie C, Degrouard J, Gillet B, Jaillard D, Laroche S, Vaillend C: Reorganization of inhibitory synapses and increased PSD length of perforated excitatory synapses in hippocampal area CA1 of dystrophin-deficient mdx mice. Cereb Cortex 2009, 19: 876–888. 10.1093/cercor/bhn135View ArticlePubMedGoogle Scholar
- Siskova Z, Mahad DJ, Pudney C, Campbell G, Cadogan M, Asuni A, O’Connor V, Perry VH: Morphological and functional abnormalities in mitochondria associated with synaptic degeneration in prion disease. Am J Pathol 2010, 177: 1411–1421. 10.2353/ajpath.2010.091037PubMed CentralView ArticlePubMedGoogle Scholar
- Weibel ER: Stereological principles for morphometry in electron microscopic cytology. Int Rev Cytol 1969, 26: 235–302.View ArticlePubMedGoogle Scholar
- Sturchler-Pierrat C, Staufenbiel M: Pathogenic mechanisms of Alzheimer’s disease analyzed in the APP23 transgenic mouse model. Ann N Y Acad Sci 2000, 920: 134–139.View ArticlePubMedGoogle Scholar
- Huang SM, Mouri A, Kokubo H, Nakajima R, Suemoto T, Higuchi M, Staufenbiel M, Noda Y, Yamaguchi H, Nabeshima T, Saido TC, Iwata N: Neprilysin-sensitive synapse-associated amyloid-beta peptide oligomers impair neuronal plasticity and cognitive function. J Biol Chem 2006, 281: 17941–17951. 10.1074/jbc.M601372200View ArticlePubMedGoogle Scholar
- Rajendran L, Annaert W: Membrane trafficking pathways in Alzheimer’s disease. Traffic 2012, 13: 759–770. 10.1111/j.1600-0854.2012.01332.xView ArticlePubMedGoogle Scholar
- Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, Lambert MP, Velasco PT, Bigio EH, Finch CE, Krafft GA, Klein WL: Synaptic targeting by Alzheimer’s-related amyloid beta oligomers. J Neurosci 2004, 24: 10191–10200. 10.1523/JNEUROSCI.3432-04.2004View ArticlePubMedGoogle Scholar
- Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ: Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat Med 2008, 14: 837–842. 10.1038/nm1782PubMed CentralView ArticlePubMedGoogle Scholar
- Wang HW, Pasternak JF, Kuo H, Ristic H, Lambert MP, Chromy B, Viola KL, Klein WL, Stine WB, Krafft GA, Trommer BL: Soluble oligomers of beta amyloid (1–42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res 2002, 924: 133–140. 10.1016/S0006-8993(01)03058-XView ArticlePubMedGoogle Scholar
- Spires TL, Meyer-Luehmann M, Stern EA, McLean PJ, Skoch J, Nguyen PT, Bacskai BJ, Hyman BT: Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J Neurosci 2005, 25: 7278–7287. 10.1523/JNEUROSCI.1879-05.2005PubMed CentralView ArticlePubMedGoogle Scholar
- Tsai J, Grutzendler J, Duff K, Gan WB: Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches. Nat Neurosci 2004, 7: 1181–1183. 10.1038/nn1335View ArticlePubMedGoogle Scholar
- McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, Skipper L, Murphy MP, Beard J, Das P, Jansen K, DeLucia M, Lin W-L, Dolios G, Wang R, Eckman CB, Dickson DW, Hutton M, Hardy J, Golde T: Aβ42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron 2005, 47: 191–199. 10.1016/j.neuron.2005.06.030PubMed CentralView ArticlePubMedGoogle Scholar
- Takuma H, Teraoka R, Mori H, Tomiyama T: Amyloid-beta E22Delta variant induces synaptic alteration in mouse hippocampal slices. Neuroreport 2008, 19: 615–619. 10.1097/WNR.0b013e3282fb78c4View ArticlePubMedGoogle Scholar
- Tomiyama T, Nagata T, Shimada H, Teraoka R, Fukushima A, Kanemitsu H, Takuma H, Kuwano R, Imagawa M, Ataka S, Wada Y, Yoshioka E, Nishizaki T, Watanabe Y, Mori H: A new amyloid beta variant favoring oligomerization in Alzheimer’s-type dementia. Ann Neurol 2008, 63: 377–387. 10.1002/ana.21321View ArticlePubMedGoogle Scholar
- Bignante EA, Heredia F, Morfini G, Lorenzo A: Amyloid beta precursor protein as a molecular target for amyloid beta–induced neuronal degeneration in Alzheimer’s disease. Neurobiol Aging 2013, 34: 2525–2537. 10.1016/j.neurobiolaging.2013.04.021PubMed CentralView ArticlePubMedGoogle Scholar
- Costa RO, Ferreiro E, Cardoso SM, Oliveira CR, Pereira CM: ER stress-mediated apoptotic pathway induced by Abeta peptide requires the presence of functional mitochondria. J Alzheimers Dis 2010, 20: 625–636.PubMedGoogle Scholar
- Wang ZF, Yin J, Zhang Y, Zhu LQ, Tian Q, Wang XC, Li HL, Wang JZ: Overexpression of tau proteins antagonizes amyloid-beta-potentiated apoptosis through mitochondria-caspase-3 pathway in N2a cells. J Alzheimers Dis 2010, 20: 145–157.PubMedGoogle Scholar
- Caspersen C, Wang N, Yao J, Sosunov A, Chen X, Lustbader JW, Xu HW, Stern D, McKhann G, Yan SD: Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer’s disease. FASEB J 2005, 19: 2040–2041.PubMedGoogle Scholar
- Dragicevic N, Mamcarz M, Zhu Y, Buzzeo R, Tan J, Arendash GW, Bradshaw PC: Mitochondrial amyloid-beta levels are associated with the extent of mitochondrial dysfunction in different brain regions and the degree of cognitive impairment in Alzheimer’s transgenic mice. J Alzheimers Dis 2010,20(Suppl 2):S535-S550.PubMedGoogle Scholar
- Du H, Guo L, Fang F, Chen D, Sosunov AA, McKhann GM, Yan Y, Wang C, Zhang H, Molkentin JD, Gunn-Moore FJ, Vonsattel JP, Arancio O, Chen JX, Yan SD: Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer’s disease. Nat Med 2008, 14: 1097–1105. 10.1038/nm.1868PubMed CentralView ArticlePubMedGoogle Scholar
- Lustbader JW, Cirilli M, Lin C, Xu HW, Takuma K, Wang N, Caspersen C, Chen X, Pollak S, Chaney M, Trinchese F, Liu S, Gunn-Moore F, Lue LF, Walker DG, Kuppusamy P, Zewier ZL, Arancio O, Stern D, Yan SS, Wu H: ABAD directly links Abeta to mitochondrial toxicity in Alzheimer’s disease. Science 2004, 304: 448–452. 10.1126/science.1091230View ArticlePubMedGoogle Scholar
- Manczak M, Anekonda TS, Henson E, Park BS, Quinn J, Reddy PH: Mitochondria are a direct site of A beta accumulation in Alzheimer’s disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet 2006, 15: 1437–1449. 10.1093/hmg/ddl066View ArticlePubMedGoogle Scholar
- Mattson MP: Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol Rev 1997, 77: 1081–1132.PubMedGoogle Scholar
- Ovsepian SV, Antyborzec I, O’Leary VB, Zaborszky L, Herms J, Oliver Dolly J: Neurotrophin receptor p75 mediates the uptake of the amyloid beta (Abeta) peptide, guiding it to lysosomes for degradation in basal forebrain cholinergic neurons. Brain Struct Funct 2013. ehead of print: doi:10.1007/s00429–013–0583-x.Google Scholar
- Ovsepian SV, Herms J: Drain of the brain: low-affinity p75 neurotrophin receptor affords a molecular sink for clearance of cortical amyloid beta by the cholinergic modulator system. Neurobiol Aging 2013, 34: 2517–2524. 10.1016/j.neurobiolaging.2013.05.005View ArticlePubMedGoogle Scholar
- Tampellini D, Magrane J, Takahashi RH, Li F, Lin MT, Almeida CG, Gouras GK: Internalized antibodies to the Abeta domain of APP reduce neuronal Abeta and protect against synaptic alterations. J Biol Chem 2007, 282: 18895–18906. 10.1074/jbc.M700373200View ArticlePubMedGoogle Scholar
- Dickson DW: The pathogenesis of senile plaques. J Neuropathol Exp Neurol 1997, 56: 321–339. 10.1097/00005072-199704000-00001View ArticlePubMedGoogle Scholar
- Wang D, Munoz DG: Qualitative and quantitative differences in senile plaque dystrophic neurites of Alzheimer’s disease and normal aged brain. J Neuropathol Exp Neurol 1995, 54: 548–556. 10.1097/00005072-199507000-00009View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.